3.65
-0.195(-5.08%)
Currency In USD
| Previous Close | 3.84 |
| Open | 3.82 |
| Day High | 3.83 |
| Day Low | 3.5 |
| 52-Week High | 6.33 |
| 52-Week Low | 2.01 |
| Volume | 4.67M |
| Average Volume | 5.34M |
| Market Cap | 548.1M |
| PE | -4.01 |
| EPS | -0.91 |
| Moving Average 50 Days | 3.69 |
| Moving Average 200 Days | 3.05 |
| Change | -0.2 |
If you invested $1000 in Absci Corporation (ABSI) since IPO date, it would be worth $168.83 as of December 14, 2025 at a share price of $3.645. Whereas If you bought $1000 worth of Absci Corporation (ABSI) shares 3 years ago, it would be worth $1,306.45 as of December 14, 2025 at a share price of $3.645.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
GlobeNewswire Inc.
Dec 11, 2025 1:00 PM GMT
Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular miniaturization and drive vellus-to-terminal hair reg
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
GlobeNewswire Inc.
Dec 10, 2025 1:00 PM GMT
Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease Donovan to share his personal journey at Absci’s upcoming Key Opinion Leader seminar VANCOUVER, Wash. and
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
GlobeNewswire Inc.
Dec 04, 2025 1:00 PM GMT
Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational trials for androgenetic alopecia (AGA) and Phase